drugset / Trial / NCT05246007

Nocturnal Low-dose Dexmedetomidine Infusion and Perioperative Sleep Quality

NCT05246007 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Night-time infusion of low-dose dexmedetomidine may improve sleep quality. However, evidence in this aspect is limited.

Timeline

Start
2022-05
Primary completion
2023-12
Completion
2026-12

Outcome

Outcome not reported

Stopped: “We changed the protocol and registered for another trial.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.025 ug/kg —

Indications